{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T07:47:59Z","timestamp":1777708079820,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"ADC Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00280-022-04487-3","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T19:18:49Z","timestamp":1667589529000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exposure\u2013response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7040-712X","authenticated-orcid":false,"given":"Marie","family":"Toukam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph P.","family":"Boni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans G.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Wuerthner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"4487_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/17474086.2017.1281122","volume":"10","author":"M Jiang","year":"2017","unstructured":"Jiang M, Bennani NN, Feldman AL (2017) Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic\/dendritic cell neoplasms. Expert Rev Hematol 10:239\u2013249. https:\/\/doi.org\/10.1080\/17474086.2017.1281122","journal-title":"Expert Rev Hematol"},{"key":"4487_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010005","author":"KC Thandra","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P (2021) Epidemiology of non-Hodgkin\u2019s lymphoma. Med Sci (Basel). https:\/\/doi.org\/10.3390\/medsci9010005","journal-title":"Med Sci (Basel)"},{"key":"4487_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Collaboration; GBoDC, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3:524\u2013548. https:\/\/doi.org\/10.1001\/jamaoncol.2016.5688","journal-title":"JAMA Oncol"},{"key":"4487_CR4","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ajh.25071","volume":"93","author":"SM Ansell","year":"2018","unstructured":"Ansell SM (2018) Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol 93:704\u2013715. https:\/\/doi.org\/10.1002\/ajh.25071","journal-title":"Am J Hematol"},{"key":"4487_CR5","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","volume":"15","author":"MJ Flynn","year":"2016","unstructured":"Flynn MJ, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE et al (2016) ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies. Mol Cancer Ther 15:2709\u20132721. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0233","journal-title":"Mol Cancer Ther"},{"key":"4487_CR6","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(21)00103-4","volume":"8","author":"M Hamadani","year":"2021","unstructured":"Hamadani M, Collins GP, Caimi PF, Samaniego F, Spira A, Davies A et al (2021) Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Lancet Haematol 8:e433\u2013e445. https:\/\/doi.org\/10.1016\/S2352-3026(21)00103-4","journal-title":"Lancet Haematol"},{"key":"4487_CR7","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"4487_CR8","unstructured":"Food and Drug Administration (1999) Guidance for industry: population pharmacokinetics. http:\/\/www.fda.gov\/downloads\/drugs\/guidances\/UCM072137.pdf. Accessed 21 Feb 2022"},{"key":"4487_CR9","unstructured":"Food and Drug Administration (2003) Guidance for industry: exposure response relationships. https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm072109.pdf. Accessed 21 Feb 2022"},{"key":"4487_CR10","unstructured":"European Medicines Agency (2007) Committee for medicinal products for human use (CHMP). Guideline on reporting the results of poulation pharmacokinetic analyses. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003067.pdf. Accessed 2 Feb 2022"},{"key":"4487_CR11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00277-011-1363-4","volume":"91","author":"N Goto","year":"2012","unstructured":"Goto N, Tsurumi H, Goto H, Shimomura YI, Kasahara S, Hara T et al (2012) Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Ann Hematol 91:705\u2013714. https:\/\/doi.org\/10.1007\/s00277-011-1363-4","journal-title":"Ann Hematol"},{"key":"4487_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/annonc\/mdv486","volume":"27","author":"M Gupta","year":"2016","unstructured":"Gupta M, Stenson M, O\u2019Byrne M, Maurer MJ, Habermann T, Cerhan JR et al (2016) Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Ralpha as predictors of event-free survival in T-cell lymphoma. Ann Oncol 27:165\u2013172. https:\/\/doi.org\/10.1093\/annonc\/mdv486","journal-title":"Ann Oncol"},{"key":"4487_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1365-2567.2010.03308.x","volume":"131","author":"CA Lindqvist","year":"2010","unstructured":"Lindqvist CA, Christiansson LH, Simonsson B, Enblad G, Olsson-Stromberg U, Loskog AS (2010) T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology 131:371\u2013376. https:\/\/doi.org\/10.1111\/j.1365-2567.2010.03308.x","journal-title":"Immunology"},{"key":"4487_CR14","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s12032-013-0723-4","volume":"30","author":"L Wang","year":"2013","unstructured":"Wang L, Liao DZ, Zhang J, Xia ZJ, Peng XW, Lu Y (2013) Clinical significance of serum soluble interleukin-2 receptor-alpha in extranodal natural killer\/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor. Med Oncol 30:723. https:\/\/doi.org\/10.1007\/s12032-013-0723-4","journal-title":"Med Oncol"},{"key":"4487_CR15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/eurjhf\/hfs007","volume":"14","author":"AP Ambrosy","year":"2012","unstructured":"Ambrosy AP, Vaduganathan M, Huffman MD, Khan S, Kwasny MJ, Fought AJ et al (2012) Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the Everest trial. Eur J Heart Fail 14:302\u2013311. https:\/\/doi.org\/10.1093\/eurjhf\/hfs007","journal-title":"Eur J Heart Fail"},{"key":"4487_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1503\/cmaj.1040752","volume":"172","author":"EG Giannini","year":"2005","unstructured":"Giannini EG, Testa R, Savarino V (2005) Liver enzyme alteration: a guide for clinicians. CMAJ 172:367\u2013379. https:\/\/doi.org\/10.1503\/cmaj.1040752","journal-title":"CMAJ"},{"key":"4487_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/blood-2020-137451","volume":"136","author":"A Herrera","year":"2020","unstructured":"Herrera A, Carlo-Stella C, Collins G, Maddocks K, Bartlett N, Savage K et al (2020) Preliminary results of a phase 2 study of camidanlumab tesirine (Cami), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in patients with relapsed or refractory Hodgkin lymphoma. Blood 136:21\u201323. https:\/\/doi.org\/10.1182\/blood-2020-137451","journal-title":"Blood"},{"key":"4487_CR18","unstructured":"clinicaltrials.gov Study to evaluate the efficacy and safety of camidanlumab tesirine (ADCT-301) in patients with relapsed or refractory Hodgkin lymphoma (NCT04052997). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04052997. Accessed 5 Jan 2022"},{"key":"4487_CR19","doi-asserted-by":"publisher","unstructured":"Toukam M, Wuerthner J, Havenith K, Hamadani M, Caimi PF, Kopotsha T et al. Population pharmacokinetics analysis of Camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. Cancer Chemother Pharmacol. https:\/\/doi.org\/10.1007\/s00280-022-04486-4","DOI":"10.1007\/s00280-022-04486-4"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04487-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04487-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04487-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T16:04:47Z","timestamp":1672848287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04487-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["4487"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04487-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]},"assertion":[{"value":"14 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M Toukam and J Boni are currently employed and current equity holders at ADC Therapeutics America, Inc., a publicly traded company. M Hamadani reports consultancy with\u202fJanssen R&D, Incyte Corporation, ADC Therapeutics, Celgene Corporation, Pharmacyclics, Omeros, AbGenomics, Verastem, TeneoBio, SeaGen, GenMab, Novartis, and Kite; membership on an entity\u2019s board of directors or advisory committees\u202ffor ADC Therapeutics;\u202fresearch funding from Takeda Pharmaceutical Company, Spectrum Pharmaceuticals, and Astellas Pharma; and\u202fspeakers bureau memberships for Sanofi Genzyme, AstraZeneca, BeiGene, and Kite Pharma. PF Caimi reports advisory board\u202fmemberships for Amgen, Bayer, Kite Pharma, ADC Therapeutics, Novartis, and Genentech; research funding for ADC Therapeutics and Genentech; and\u202fspeakers bureau membership for Celgene. HG Cruz and J Wuerthner are currently employed and current equity holders at ADC Therapeutics SA, a publicly traded company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}